{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260817879631/en/ENHERTU%C2%AE-fam-trastuzumab-deruxtecan-nxki-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-PFS-as-1st-line-treatment-of-patients-with-HER2-mutant-advanced-non-small-cell-lung-cancer-in-DESTINY-Lung04-Phase-III-trial", "message": "News view counter 886492 successfully enlarged"}